Pharmacodynamics and Pharmacokinetics of Different Modes of Rocuronium Administration

  • H. J. Sparr
  • K. S. Khuenl-Brady
  • F. K. Puehringer
  • Ch. Kolbitsch
  • S. Agoston
Conference paper


Rocuronium (Org 9426), which has recently been introduced in clinical practice, is the 2-morpholino, 3-hydroxy, 16N-allyl-pyrrolidino derivative of vecuronium. In contrast to vecuronium no pharmacologically active metabolites of this compound have been found in man. Its neuromuscular blocking potency is about 7 times less than that of vecuronium [1,2]. Rocuronium has intermediate duration of action, and after several maintenance doses of rocuronium no tendency toward cumulation was shown [3,4]. Therefore, rocuronium might be suitable for prolonged administration in critically ill patients (ICU-patients). However, neuromuscular blocking agents are developed and tested for use once or twice in a life-time, usually in surgical patients. No information has been available so far on the administration of rocuronium in critically ill patients .


Surgical Patient Neuromuscular Blocking Agent Infusion Group Peripheral Nerve Stimulator Rocuronium Bromide 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wierda JMKH, de Wit APM, Kuizenga K, Agoston S (1990) Clinical observations on the neuromuscular blocking action of Org 9426, a new steroidal non depolarizing agent. Br J Anaesth 64;521–523PubMedCrossRefGoogle Scholar
  2. 2.
    Bartkowski RR, Witkowski TA, Azad S, Lessin J, Man A (1993) Rocuronium onset of action: acomparison with atracurium and vecuronium. Anesth Analg 77:574–578PubMedCrossRefGoogle Scholar
  3. 3.
    Khuenl-Brady KS, Puehringer F, Koller J, Mitterschiffthaler G (1993) Evaluation of the time course of action of maintenance doses of rocuronium (ORG 9426) under halothane anaesthesia. Acta Anaesthesiol Scand 37:137–139PubMedCrossRefGoogle Scholar
  4. 4.
    Khuenl-Brady KS, Pomaroli A, Puehringer F, Mitterschiffthaler G, Koller J (1993) The use of rocuronium (ORG 9426) in patients with chronic renal failure. Anaesthesia 48:873–875PubMedCrossRefGoogle Scholar
  5. 5.
    Sparr HJ, Khuenl-Brady KS, Eriksson LI (1994) Pharmacodynamics and pharmacokinetics of rocuronium following continuous infusion in patients during intravenous anaesthesia. Eur J Anaesth 11 (Suppl. 9): 63–65Google Scholar
  6. 6.
    Rowaan CJ, Vandenbrom RHG, Wierda JMKH (1993) The Relaxometer: a complete and comprehensive computer-controlled neuromuscular transmission measurement system developed for clinical research on muscle relaxants. J Clin Monit 9:38–44PubMedCrossRefGoogle Scholar
  7. 7.
    Viby Mogensen J(1993) Monitoring neuromuscular function in the intensive care unit. Intensive Care Med 19 (Suppl 2):S74–79CrossRefGoogle Scholar
  8. 8.
    Kleef UW, Proost JH, Roggeveld J, Wierda JMKH (1993) Determination of rocuronium and its putative metabolites in body fluids and tissue homogenates. J Chromatogr / Biomedical Applications 621;65–76CrossRefGoogle Scholar
  9. 9.
    Wagner JG (1979) Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications Inc, Hamilton Illinois, USAGoogle Scholar
  10. 10.
    Wierda JMKH, Kleef UW, Lambalk LM, Kloppenburg WD, Agoston S (1991) The pharmacokinetics and pharacodynamics of Org 9426, a new non depolarazing neurmuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J Anaesth 38:435–435Google Scholar
  11. 11.
    Shanks CA, Fragen RJ, Ling D (1993) Continuous intravenous infusion of rocuronium (ORG 942) in patients receiving balanced, enflurane, or isoflurane anesthesia. Anesthesiology 78:649651PubMedCrossRefGoogle Scholar
  12. 12.
    Olkkola KT, Tammisto T (1994) Quantifying the interaction of rocuronium (Org 9426) with etomidate, fentanyl, midazolam, propofol, thiopental, and isoflurane using closed-loop feedback control of rocuronium infusion. Anesth Analg 78:691–696PubMedCrossRefGoogle Scholar
  13. 13.
    Cooper RA, Mirakhur RK, Maddineni VR (1993) Neuromuscular effects of rocuronium bromide (Org 9426) during fentanyl and halothane anaesthesia. Anaesthesia 48:103–105PubMedCrossRefGoogle Scholar
  14. 14.
    Segredo V, Caldwell JE, Matthay MA, Sharma ML, Gruenke LD, Miller RD (1992) Persistent paralysis in critically ill patients after long-term administration of vecuronium. NEJM 327:524528.PubMedCrossRefGoogle Scholar
  15. 15.
    Pollard BJ (1993) Neuromuscular blocking agents in intensive care. Intensive Care Med 1993;19 (Suppl 2):536–39Google Scholar
  16. 16.
    Watling SM, Dasta JF (1994) Prolonged paralysis in intensive care unit patients after the use of neuromuscular blocking agents: A review of the literature. Crit Care Med 22:884–893PubMedCrossRefGoogle Scholar
  17. 17.
    Caldwell JE, Szenohradszky J, Segredo V, Wright PMC, McLoughlin C, Sharma ML, Gruenke LD, Fisher DM, Miller RD (1994) The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers. J Pharmacol Exp Ther 270:1216–1222PubMedGoogle Scholar

Copyright information

© Springer Japan 1995

Authors and Affiliations

  • H. J. Sparr
    • 1
  • K. S. Khuenl-Brady
    • 1
  • F. K. Puehringer
    • 1
  • Ch. Kolbitsch
    • 1
  • S. Agoston
    • 1
    • 2
  1. 1.Department of Anaesthesia and Intensive Care MedicineUniversity of InnsbruckInnsbruckAustria
  2. 2.Research Group on Experimental Anaesthesiology and Clinical Pharmacology, Department of AnaesthesiologyUniversity HospitalGroningenThe Netherlands

Personalised recommendations